The ALK translocation in advanced non-small-cell lung carcinomas: Preapproval testing experience at a single cancer centre
Carcinoma, Non-Small-Cell Lung
Receptor Protein-Tyrosine Kinases
The prevalence of ALK translocation in an unselected population of European patients with advanced NSCLCs was 10%. This alteration was mutually exclusive with EGFR and KRAS mutations, as well as with MET amplification. If multiplexing is considered at the preanalytical phase, lung biopsy specimens are sufficient for performing several predictive assays.